Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Impact of High Molecular Risk Mutations on Overall Survival in WHO-Defined Essential Thrombocythemia and Prefibrotic Primary Myelofibrosis

Heinz Gisslinger, Martin Schalling, Bettina Gisslinger, Roland Jäger, PhD, Edith Bogner, Ashot S Harutyunyan, PhD, Jelena D Milosevic Feenstra, Nicole C.C. Them, Maria-Theresa Krauth, MD, Leonhard Muellauer, MD, Juergen Thiele, MD PhD, Robert Kralovics

Blood (2016) 128 (22): 1931.

https://doi.org/10.1182/blood.V128.22.1931.1931

Published: 2016

Journal Articles

LNK mutations in familial myeloproliferative neoplasms

Elisa Rumi, Ashot S. Harutyunyan, Daniela Pietra, Jelena D. Milosevic Feenstra, Chiara Cavalloni, Elisa Roncoroni, Ilaria Casetti, Marta Bellini, Chiara Milanesi, Maria C. Renna, Manuel Gotti, Cesare Astori, Robert Kralovics, Mario Cazzola

Blood (2016) 128 (1): 144–145.

https://doi.org/10.1182/blood-2016-04-711150

Published: 2016

Journal Articles

Germline RBBP6 mutations in familial myeloproliferative neoplasms

Blood (2016) 127 (3): 362–365.

https://doi.org/10.1182/blood-2015-09-668673

Published: 2016

Includes: Supplemental data

Journal Articles

Common Variation at 6q25.3 ( TULP4 ) Influences Risk for Arterial Thrombosis in Myeloproliferative Neoplasms

Roland Jäger, PhD, Ashot S Harutyunyan, PhD, Elisa Rumi, MD, Bettina Gisslinger, Martin Schalling, MSc, Virginia Ferretti, PhD, Daniela Pietra, PhD, Mario Cazzola, MD, Heinz Gisslinger, MD, Robert Kralovics, PhD

Blood (2015) 126 (23): 4088.

https://doi.org/10.1182/blood.V126.23.4088.4088

Published: 2015

Journal Articles

Calreticulin Mutation Status Predicts Improved Disease Outcome in Prefibrotic Primary Myelofibrosis but Not in WHO-Defined Essential Thrombocythemia

Heinz Gisslinger, MD, Juergen Thiele, MD PhD, Bettina Gisslinger, MSc, Tiina Berg, B.Sc., Martin Schalling, M.Sc., Ashot S Harutyunyan, MD, Jelena D. Milosevic, M.Sc., Klaudia Bagienski, M.Sc., Nicole C.C. Them, M.Sc., Veronika Buxhofer-Ausch, Guenther Nirnberger, Leonhard Muellauer, MD, Robert Kralovics, PhD

Blood (2014) 124 (21): 3167.

https://doi.org/10.1182/blood.V124.21.3167.3167

Published: 2014

Journal Articles

CALR exon 9 mutations are somatically acquired events in familial cases of essential thrombocythemia or primary myelofibrosis

Elisa Rumi, Ashot S. Harutyunyan, Daniela Pietra, Jelena D. Milosevic, Ilaria C. Casetti, Marta Bellini, Nicole C. C. Them, Chiara Cavalloni, Virginia V. Ferretti, Chiara Milanesi, Tiina Berg, Emanuela Sant’Antonio, Emanuela Boveri, Cristiana Pascutto, Cesare Astori, Robert Kralovics, Mario Cazzola

Blood (2014) 123 (15): 2416–2419.

https://doi.org/10.1182/blood-2014-01-550434

Published: 2014

Includes: Supplemental data

Journal Articles

JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes

Blood (2014) 123 (10): 1544–1551.

https://doi.org/10.1182/blood-2013-11-539098

Published: 2014

Includes: Supplemental data

Journal Articles

Germ-line JAK2 mutations in the kinase domain are responsible for hereditary thrombocytosis and are resistant to JAK2 and HSP90 inhibitors

Caroline Marty, Cécile Saint-Martin, Christian Pecquet, Sarah Grosjean, Joseph Saliba, Céline Mouton, Emilie Leroy, Ashot S. Harutyunyan, Jean-François Abgrall, Rémi Favier, Aurélie Toussaint, Eric Solary, Robert Kralovics, Stefan N. Constantinescu, Albert Najman, William Vainchenker, Isabelle Plo, Christine Bellanné-Chantelot

Blood (2014) 123 (9): 1372–1383.

https://doi.org/10.1182/blood-2013-05-504555

Published: 2014

Includes: Supplemental data

Journal Articles

Frequent Mutations in the Calreticulin Gene CALR in Myeloproliferative Neoplasms

Blood (2013) 122 (21): LBA-1.

https://doi.org/10.1182/blood.V122.21.LBA-1.LBA-1

Published: 2013

Journal Articles

Germline JAK2 Mutations In The Kinase Domain Are Responsible For Hereditary Thrombocytosis and Are Resistant To JAK2 and HSP90 Inhibitors

Caroline Marty, Ph.D, Cecile Saint-martin, Christian Pecquet, PhD, Sarah Grosjean, Joseph Saliba, PhD Student, Celine Mouton, Leroy Emilie, Ashot S. Harutyunyan, Jean-François Abgrall, Remy Favier, Eric Solary, Robert Kralovics, PhD, Stefan N. Constantinescu, MD, PhD, Albert Najman, MD, William Vainchenker, MD, PhD, Isabelle Plo, Ph.D, Christine Bellanné-Chantelot

Blood (2013) 122 (21): 1603.

https://doi.org/10.1182/blood.V122.21.1603.1603

Published: 2013

Journal Articles

Germline RBBP6 Mutations In Myeloproliferative Neoplasms

Blood (2013) 122 (21): 267.

https://doi.org/10.1182/blood.V122.21.267.267

Published: 2013

NARROW

Impact of High Molecular Risk Mutations on Overall Survival in WHO-Defined Essential Thrombocythemia and Prefibrotic Primary Myelofibrosis

LNK mutations in familial myeloproliferative neoplasms

Germline RBBP6 mutations in familial myeloproliferative neoplasms

Common Variation at 6q25.3 ( TULP4 ) Influences Risk for Arterial Thrombosis in Myeloproliferative Neoplasms

Calreticulin Mutation Status Predicts Improved Disease Outcome in Prefibrotic Primary Myelofibrosis but Not in WHO-Defined Essential Thrombocythemia

CALR exon 9 mutations are somatically acquired events in familial cases of essential thrombocythemia or primary myelofibrosis

JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes

Germ-line JAK2 mutations in the kinase domain are responsible for hereditary thrombocytosis and are resistant to JAK2 and HSP90 inhibitors

Frequent Mutations in the Calreticulin Gene CALR in Myeloproliferative Neoplasms

Germline JAK2 Mutations In The Kinase Domain Are Responsible For Hereditary Thrombocytosis and Are Resistant To JAK2 and HSP90 Inhibitors

Germline RBBP6 Mutations In Myeloproliferative Neoplasms

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only